Cargando…

Real-world data confirm clinical trial outcomes for rivaroxaban in orthopaedic patients

Venous thromboembolism (VTE) is a potential cause of morbidity and mortality in patients after major orthopaedic surgery. Based on the results of the international phase III RECORD (Regulation of Coagulation in Orthopaedic Surgery to Prevent Deep Vein Thrombosis and Pulmonary Embolism) program, the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kwong, Louis, Turpie, Alexander G.G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2015
Materias:	Review Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4420150/ https://www.ncbi.nlm.nih.gov/pubmed/25973138 http://dx.doi.org/10.1097/BCO.0000000000000232

Ejemplares similares

Impact of gender: Rivaroxaban for patients with atrial fibrillation in the XANTUS real‐world prospective study
por: Camm, A. John, et al.
Publicado: (2020)

Rivaroxaban for venous thromboembolism prevention after major orthopedic surgery: translating trial data into routine clinical practice
por: Beyer-Westendorf, Jan, et al.
Publicado: (2017)

Rivaroxaban as an oral anticoagulant for stroke prevention in atrial fibrillation
por: Turpie, Alexander GG
Publicado: (2014)

Advances in oral anticoagulation treatment: the safety and efficacy of rivaroxaban in the prevention and treatment of thromboembolism
por: Turpie, Alexander G.G.
Publicado: (2012)

XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation
por: Camm, A. John, et al.
Publicado: (2016)

Rivaroxaban compared with standard thromboprophylaxis after major orthopaedic surgery: co‐medication interactions
por: Kreutz, Reinhold, et al.
Publicado: (2016)

Practical guidance for using rivaroxaban in patients with atrial fibrillation: balancing benefit and risk
por: Haas, Sylvia, et al.
Publicado: (2014)

XANTUS-EL: A real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation in Eastern Europe, Middle East, Africa and Latin America
por: Martínez, Carlos Arturo Areán, et al.
Publicado: (2018)

International longitudinal registry of patients with atrial fibrillation and treated with rivaroxaban: RIVaroxaban Evaluation in Real life setting (RIVER)
por: Beyer-Westendorf, Jan, et al.
Publicado: (2019)

XANTUS: rationale and design of a noninterventional study of rivaroxaban for the prevention of stroke in patients with atrial fibrillation
por: Camm, A John, et al.
Publicado: (2014)

XALIA: rationale and design of a non-interventional study of rivaroxaban compared with standard therapy for initial and long-term anticoagulation in deep vein thrombosis
por: Ageno, Walter, et al.
Publicado: (2014)

Rivaroxaban and apixaban in patients with atrial fibrillation; a real-world data
por: ASLAN, Onur, et al.
Publicado: (2022)

Therapeutic potential of rivaroxaban in the prevention of venous thromboembolism following hip and knee replacement surgery: a review of clinical trial data
por: Kwong, Louis M
Publicado: (2011)

Rationale and design of XAMOS: noninterventional study of rivaroxaban for prophylaxis of venous thromboembolism after major hip and knee surgery
por: Turpie, Alexander GG, et al.
Publicado: (2012)

Real-world outcomes of rivaroxaban treatment in elderly Japanese patients with nonvalvular atrial fibrillation
por: Kitazono, Takanari, et al.
Publicado: (2019)

Rivaroxaban and the EINSTEIN clinical trial programme
por: Cohen, Alexander T., et al.
Publicado: (2019)

Benefit–risk assessment of rivaroxaban versus enoxaparin for the prevention of venous thromboembolism after total hip or knee arthroplasty
por: Levitan, Bennett, et al.
Publicado: (2014)

Rivaroxaban Precision Dosing Strategy for Real‐World Atrial Fibrillation Patients
por: Konicki, Robyn, et al.
Publicado: (2020)

Real‐World Rivaroxaban and Apixaban Levels in Asian Patients With Atrial Fibrillation
por: Lin, Shin‐Yi, et al.
Publicado: (2019)

Outcomes associated with under-dosing of rivaroxaban for management of non-valvular atrial fibrillation in real-world Japanese clinical settings
por: Ikeda, Takanori, et al.
Publicado: (2019)

Rivaroxaban and apixaban in orthopaedics: is there a difference in their plasma concentrations and anticoagulant effects?
por: Freyburger, Geneviève, et al.
Publicado: (2015)

Fondaparinux in the management of patients with ST-elevation acute myocardial infarction
por: Turpie, Alexander GG
Publicado: (2006)

Impact of Modifiable Bleeding Risk Factors on Major Bleeding in Patients With Atrial Fibrillation Anticoagulated With Rivaroxaban
por: Kirchhof, Paulus, et al.
Publicado: (2020)

Trends in prescribing and outcomes in obese versus non-obese patients receiving rivaroxaban therapy: an observational study using real-world data
por: Alalawneh, Majdoleen, et al.
Publicado: (2023)

Subgroup Analysis of Patients with Cancer in XALIA: A Noninterventional Study of Rivaroxaban versus Standard Anticoagulation for VTE
por: Ageno, Walter, et al.
Publicado: (2017)

Nonvitamin K antagonist oral anticoagulant use in patients with renal impairment
por: Turpie, Alexander G.G., et al.
Publicado: (2017)

Impact of body mass index on real-world outcomes of rivaroxaban treatment in Japanese patients with non-valvular atrial fibrillation
por: Murakawa, Yuji, et al.
Publicado: (2020)

Real-world Experience in Managing Atrial Fibrillation in Patients with Renal Impairment; Rivaroxaban versus Warfarin
por: Albabtain, Monirah Abdulrahman, et al.
Publicado: (2023)

A Systematic Review of Network Meta-Analyses and Real-World Evidence Comparing Apixaban and Rivaroxaban in Nonvalvular Atrial Fibrillation
por: Hill, Nathan R., et al.
Publicado: (2020)

Real-world comparison of bleeding risks among non-valvular atrial fibrillation patients prescribed apixaban, dabigatran, or rivaroxaban
por: Tepper, Ping G., et al.
Publicado: (2018)

Daptomycin for the treatment of osteomyelitis and orthopaedic device infections: real-world clinical experience from a European registry
por: Malizos, K., et al.
Publicado: (2015)

Comparative safety and efficacy of antithrombotics in the management of venous thromboembolism after knee or hip replacement surgery: focus on rivaroxaban
por: Kwong, Louis M
Publicado: (2013)

Real World Comparison of Rivaroxaban and Warfarin in Korean Patients with Atrial Fibrillation: Propensity Matching Cohort Analysis
por: Jeong, Hyung Ki, et al.
Publicado: (2019)

Efficacy and Safety of Rivaroxaban versus Warfarin for the Treatment of Acute Pulmonary Embolism: A Real-World Study
por: Huang, Yan, et al.
Publicado: (2020)

Comparative Effectiveness of Apixaban and Rivaroxaban Lead-in Dosing in VTE Treatment: Observational Multicenter Real-World Study
por: Alshaya, Omar A., et al.
Publicado: (2022)

Patient-Reported Treatment Experience with Oral Rivaroxaban: Results from the Noninterventional XALIA Study of Deep-Vein Thrombosis
por: Cano, Stefan, et al.
Publicado: (2018)

Using real-world data for supporting regulatory decision making: Comparison of cardiovascular and safety outcomes of an empagliflozin randomized clinical trial versus real-world data
por: Jang, Ha Young, et al.
Publicado: (2022)

Real-world experience with histological confirmation of clinical response of squamous cell carcinoma to topical tirbanibulin
por: Moore, Angela, et al.
Publicado: (2023)

Real-life use of Rivaroxaban in the Netherlands: data from the Xarelto for Prevention of Stroke in Patients with Atrial Fibrillation (XANTUS) registry
por: Pisters, R., et al.
Publicado: (2017)

Improving Realism in Clinical Trial Simulations via Real‐World Data
por: Kimko, Holly, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_dtlkuorunojgfgfkkh4dt7f1ut